|
Name |
Lead bis(2-ethylhexanoate)
|
Molecular Formula | C16H30O4Pb | |
IUPAC Name* |
2-ethylhexanoate;lead(2+)
|
|
SMILES |
CCCCC(CC)C(=O)[O-].CCCCC(CC)C(=O)[O-].[Pb+2]
|
|
InChI |
InChI=1S/2C8H16O2.Pb/c2*1-3-5-6-7(4-2)8(9)10;/h2*7H,3-6H2,1-2H3,(H,9,10);/q;;+2/p-2
|
|
InChIKey |
RUCPTXWJYHGABR-UHFFFAOYSA-L
|
|
Synonyms |
Lead bis(2-ethylhexanoate); 301-08-6; Lead(II) 2-ethylhexanoate; 2-ethylhexanoate;lead(2+); Hexanoic acid, 2-ethyl-, lead(2+) salt (2:1); Hexanoic acid, 2-ethyl-, lead salt; Lead tallate 2-ethylhexanoate; EINECS 206-107-0; EINECS 269-090-9; MFCD00014003; SCHEMBL43687; SCHEMBL2423179; DTXSID50890498; 2-Ethylhexanoic acid lead(II) salt; Bis(2-ethylhexanoic acid)lead(II) salt; 68187-37-1; DB-047708; FT-0631914
|
|
CAS | 301-08-6 | |
PubChem CID | 160451 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 493.0 | ALogp: | -0.1 |
HBD: | 0 | HBA: | 4 |
Rotatable Bonds: | 8 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 80.3 | Aromatic Rings: | 0 |
Heavy Atoms: | 21 | QED Weighted: | 0.406 |
Caco-2 Permeability: | -4.279 | MDCK Permeability: | 0.00003020 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.17 |
Blood-Brain-Barrier Penetration (BBB): | 0.996 | Plasma Protein Binding (PPB): | 60.36% |
Volume Distribution (VD): | 0.713 | Fu: | 39.91% |
CYP1A2-inhibitor: | 0.063 | CYP1A2-substrate: | 0.48 |
CYP2C19-inhibitor: | 0.028 | CYP2C19-substrate: | 0.883 |
CYP2C9-inhibitor: | 0.103 | CYP2C9-substrate: | 0.925 |
CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.143 |
CYP3A4-inhibitor: | 0.005 | CYP3A4-substrate: | 0.085 |
Clearance (CL): | 4.138 | Half-life (T1/2): | 0.674 |
hERG Blockers: | 0.025 | Human Hepatotoxicity (H-HT): | 0.697 |
Drug-inuced Liver Injury (DILI): | 0.037 | AMES Toxicity: | 0.024 |
Rat Oral Acute Toxicity: | 0.059 | Maximum Recommended Daily Dose: | 0.03 |
Skin Sensitization: | 0.737 | Carcinogencity: | 0.444 |
Eye Corrosion: | 0.981 | Eye Irritation: | 0.988 |
Respiratory Toxicity: | 0.704 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000628 | 0.443 | D03LGY | 0.472 | ||||
ENC000213 | 0.404 | D0X4FM | 0.391 | ||||
ENC001132 | 0.397 | D0Y3KG | 0.274 | ||||
ENC002444 | 0.393 | D0AY9Q | 0.267 | ||||
ENC003061 | 0.392 | D08EVN | 0.258 | ||||
ENC001041 | 0.391 | D0D9NY | 0.247 | ||||
ENC000290 | 0.379 | D00MLW | 0.245 | ||||
ENC001248 | 0.375 | D0ZI4H | 0.245 | ||||
ENC002794 | 0.368 | D06ORU | 0.223 | ||||
ENC000833 | 0.367 | D0N3NO | 0.221 |